Related Experiment Videos
Saxagliptin for type 2 diabetes.
1Diabetes Center, Federal University of São Paulo, Brazil.
Summary
Saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, effectively improves glycemic control in type 2 diabetes. This drug demonstrated significant reductions in HbA1c and fasting glucose without increasing hypoglycemia or weight gain.
Area of Science:
- Pharmacology and Endocrinology
- Metabolic Diseases
- Clinical Therapeutics
Background:
- Type 2 diabetes (T2D) is a prevalent metabolic disorder requiring effective glycemic control.
- Dipeptidyl peptidase-4 (DPP-4) inhibitors represent a class of oral antidiabetic agents.
- Saxagliptin is a selective DPP-4 inhibitor developed for T2D management.
Purpose of the Study:
- To evaluate the efficacy and safety of saxagliptin in improving glycemic control in patients with T2D.
- To assess the impact of saxagliptin on beta-cell function and cardiovascular risk.
- To determine the role of saxagliptin as monotherapy or in combination with other antidiabetic agents.
Main Methods:
- Controlled clinical trials were conducted to assess saxagliptin's effects.
- Glycemic parameters including HbA1c, fasting plasma glucose, and postprandial glucose were measured.
- Beta-cell function was assessed using homeostasis model assessment (HOMA)-2β.
- A meta-analysis of Phase II and III trials evaluated cardiovascular safety.
Main Results:
- Saxagliptin significantly reduced HbA1c levels in monotherapy and combination therapies.
- Significant decreases in fasting and postprandial glucose were observed.
- Improvements in beta-cell function (HOMA-2β) were noted with saxagliptin treatment.
- Saxagliptin was well-tolerated, weight-neutral, and did not increase hypoglycemia risk.
- A meta-analysis confirmed no increased risk of major cardiovascular events.
Conclusions:
- Saxagliptin is an effective and well-tolerated DPP-4 inhibitor for improving glycemic control in T2D.
- It offers benefits in beta-cell function and has a favorable cardiovascular safety profile.
- Clinical guidelines now recommend DPP-4 inhibitors, including saxagliptin, as early treatment options for T2D.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...